{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:22:09Z","timestamp":1790680929081,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"DOI":"10.1182\/bloodadvances.2022007126","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T20:04:08Z","timestamp":1662667448000},"page":"2580-2585","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-5908","authenticated-orcid":false,"given":"Harry J.","family":"Iland","sequence":"first","affiliation":[{"name":"1Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-8155","authenticated-orcid":false,"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Guy's and St Thomas' Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"3Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-1940","authenticated-orcid":false,"given":"Aditya","family":"Tedjaseputra","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew","family":"Wei","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-5625","authenticated-orcid":false,"given":"Asim","family":"Khwaja","sequence":"additional","affiliation":[{"name":"6Department of Haematology, University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-4441","authenticated-orcid":false,"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[{"name":"7Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-6209","authenticated-orcid":false,"given":"Steven W.","family":"Lane","sequence":"additional","affiliation":[{"name":"8Cancer Care Services, Royal Brisbane & Women\u2019s Hospital and University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"9Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0204","authenticated-orcid":false,"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[{"name":"10School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise","family":"Martin","sequence":"additional","affiliation":[{"name":"11Haematology Department, Royal Perth Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tan","sequence":"additional","affiliation":[{"name":"11Haematology Department, Royal Perth Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[{"name":"12Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anny","family":"Wong","sequence":"additional","affiliation":[{"name":"13Department of Paediatric Oncology and Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Taper","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Nepean Hospital, Nepean, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fraga","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Department of Medicine, Dalhousie University, Halifax, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kelly","sequence":"additional","affiliation":[{"name":"16Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Tawana","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Addenbrookes Hospital, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-1705","authenticated-orcid":false,"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[{"name":"18Bristol Haematology and Oncology Centre, University Hospitals of Bristol and Weston NHS Trusts, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mina","sequence":"additional","affiliation":[{"name":"19Division of Bone Marrow Transplant and Cellular Therapies, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-1896","authenticated-orcid":false,"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"20Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"M\u00f8lle","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-970X","authenticated-orcid":false,"given":"Sudhir","family":"Tauro","sequence":"additional","affiliation":[{"name":"22Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[{"name":"23Department of Adult Haematology, Manchester Royal Infirmary, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"15","key":"2023061215530264800_bib1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2023061215530264800_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.seminhematol.2018.07.004","article-title":"Curative strategies in APL","volume":"56","author":"Iland","year":"2019","journal-title":"Semin Hematol"},{"issue":"4","key":"2023061215530264800_bib3","first-page":"1247","article-title":"Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2023061215530264800_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023061215530264800_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023061215530264800_bib6","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial","volume":"2","author":"Iland","year":"2015","journal-title":"The Lancet Haematology"},{"issue":"10","key":"2023061215530264800_bib7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023061215530264800_bib8","doi-asserted-by":"crossref","first-page":"e2020382118","DOI":"10.1073\/pnas.2020382118","article-title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","volume":"118","author":"Chen","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2023061215530264800_bib9","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1200\/JCO.2008.18.4119","article-title":"Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience","volume":"27","author":"Kelaidi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023061215530264800_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inf"},{"issue":"9","key":"2023061215530264800_bib11","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"De Stefano","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023061215530264800_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3324\/haematol.2011.047506","article-title":"Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia","volume":"97","author":"Iland","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2023061215530264800_bib13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2013.842985","article-title":"Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype","volume":"55","author":"Poire","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023061215530264800_bib14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s12032-012-0251-7","article-title":"Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)","volume":"29","author":"Wiernik","year":"2012","journal-title":"Med Oncol"},{"issue":"7","key":"2023061215530264800_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.leukres.2010.01.001","article-title":"Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review","volume":"34","author":"Beitinjaneh","year":"2010","journal-title":"Leuk Res"},{"issue":"7","key":"2023061215530264800_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2023061215530264800_bib17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2023061215530264800_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12931","article-title":"Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study","volume":"166","author":"Paulson","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2023061215530264800_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2023061215530264800_bib20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2023061215530264800_bib21","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023061215530264800_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V99.3.822","article-title":"Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem","volume":"99","author":"Latagliata","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2023061215530264800_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/sj.leu.2403034","article-title":"Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience","volume":"17","author":"Lobe","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"2023061215530264800_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ajh.21528","article-title":"Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia","volume":"84","author":"Batzios","year":"2009","journal-title":"Am J Hematol"},{"issue":"26","key":"2023061215530264800_bib25","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2010-06-289389","article-title":"Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia","volume":"116","author":"Imagawa","year":"2010","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2580\/2056777\/blooda_adv-2022-007126-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2580\/2056777\/blooda_adv-2022-007126-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:53:52Z","timestamp":1686585232000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2580\/486553\/Characteristics-and-outcomes-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007126","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}